IDEXX Laboratories - IDXX Stock Forecast, Price & News

8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for IDEXX Laboratories in the last year. There are currently 2 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" IDXX shares.
View IDXX analyst ratings or view top-rated stocks.

8 Wall Street research analysts have issued twelve-month price objectives for IDEXX Laboratories' shares. Their IDXX share price forecasts range from $415.00 to $582.00. On average, they expect the company's stock price to reach $483.57 in the next year. This suggests a possible upside of 38.7% from the stock's current price.
View analysts price targets for IDXX or view top-rated stocks among Wall Street analysts.

IDEXX Laboratories' stock was trading at $658.46 at the start of the year. Since then, IDXX stock has decreased by 47.1% and is now trading at $348.59.
View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 1st 2022.
View our IDXX earnings forecast.

IDEXX Laboratories, Inc. (NASDAQ:IDXX) announced its quarterly earnings results on Tuesday, August, 2nd. The company reported $1.56 earnings per share for the quarter, topping analysts' consensus estimates of $1.54 by $0.02. The firm earned $860.55 million during the quarter, compared to the consensus estimate of $864.26 million. IDEXX Laboratories had a trailing twelve-month return on equity of 104.47% and a net margin of 20.07%.

IDEXX Laboratories issued an update on its FY 2022 earnings guidance on Tuesday, August, 9th. The company provided earnings per share guidance of $7.77-$8.05 for the period, compared to the consensus EPS estimate of $8.27. The company issued revenue guidance of $3.31 billion-$3.38 billion, compared to the consensus revenue estimate of $3.42 billion.

40 employees have rated IDEXX Laboratories Chief Executive Officer Jay Mazelsky on Glassdoor.com. Jay Mazelsky has an approval rating of 69% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other IDEXX Laboratories investors own include NVIDIA (NVDA), Netflix (NFLX), PayPal (PYPL), Mastercard (MA), Adobe (ADBE), Tesla (TSLA), Alibaba Group (BABA), Block (SQ), Walt Disney (DIS) and Shopify (SHOP).

IDEXX Laboratories trades on the NASDAQ under the ticker symbol "IDXX."

IDEXX Laboratories' stock is owned by a number of retail and institutional investors. Top institutional investors include Spence Asset Management (0.05%) and Capital Investment Services of America Inc. (0.05%). Insiders that own company stock include Brian P Mckeon, Brian P Mckeon, Bruce L Claflin, Daniel M Junius, Giovani Twigge, James F Polewaczyk, James F Polewaczyk, Jonathan Jay Mazelsky, Jonathan W Ayers, Jonathan W Ayers, Kathy V Turner, Kathy V Turner, M Anne Szostak, Michael Lane, Nimrata Hunt, Rebecca M Henderson and Sophie V Vandebroek.
View institutional ownership trends.

Shares of IDXX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of IDXX stock can currently be purchased for approximately $348.59.

IDEXX Laboratories (NASDAQ:IDXX) has a market capitalization of $29.02 billion and generates $3.22 billion in revenue each year. The company earns $744.84 million in net income (profit) each year or $7.75 on an earnings per share basis.

The company employs 10,350 workers across the globe.

IDEXX Laboratories' mailing address is ONE IDEXX DRIVE, WESTBROOK ME, 04092. The official website for the company is www.idexx.com. The company can be reached via phone at (207) 556-0300, via email at investorrelations@idexx.com, or via fax at 207-556-4346.